<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993456</url>
  </required_header>
  <id_info>
    <org_study_id>TJ-CT-POAF</org_study_id>
    <nct_id>NCT04993456</nct_id>
  </id_info>
  <brief_title>Calcitonin Level and New-onset of Post-Operative Atrial Fibrillation</brief_title>
  <official_title>Division of Cardiology, Department of Internal Medicne, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-operative atrial fibrillation (POAF) is one of the common complicaiton following cardiac&#xD;
      surgery, occurring in approximately 20%-40% patients. Although POAF is associated with longer&#xD;
      hospital stays, most POAF is short lived and resolves in the 2-4 days afer cardiac surgery.&#xD;
&#xD;
      However, a recent meta-analysis showed significant increases in 1,5, and 10 year mortality in&#xD;
      POAF patients (odds ratio:1.60, 2.60, 1.51;95% confidence intervals: 1.52 to 1.68, 2.00 to&#xD;
      3.38, 1.43 to 1.60;P &lt;0.0001), the combined adjusted risk of death (16 studies, n =84,295)&#xD;
      was also significantly increased in patients with POAF (hazard ratio: 1.25;95% confidence&#xD;
      interval: 1.2-1.3;P &lt; 0.0001).&#xD;
&#xD;
      These data highlight the need to understand better the underlying mechanism of POAF. A latest&#xD;
      research in Nature reported levels of circulating calcitonin (CT), which is the main risk&#xD;
      factor for atrial fibrillation (AF). Global disruption of CT receptor signalling in mice&#xD;
      causes atrial fibrosis and increases susceptibility to AF.&#xD;
&#xD;
      Here we will explore the relationship between CT and POAF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">July 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>POAF lasting longer than 30 seconds during the first week after cardiac surgery</measure>
    <time_frame>2 years after cardiac surgery</time_frame>
    <description>The incidence of atrial fibrillation lasting longer than 30 seconds during the first week after cardiac surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The hospitalization days</measure>
    <time_frame>2 years after cardiac surgery</time_frame>
    <description>The length of stay after the cardiac surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular rate of the atrial fibrillation</measure>
    <time_frame>2 years after cardiac surgery</time_frame>
    <description>Ventricular rate of atrial fibrillation after the cardiac surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of serum calcitonin</measure>
    <time_frame>2 years after cardiac surgery</time_frame>
    <description>Levels of serum calcitonin of atrial fibrillation after the cardiac surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of serum procalcitonin</measure>
    <time_frame>2 years after cardiac surgery</time_frame>
    <description>Levels of serum procalcitonin of atrial fibrillation after the cardiac surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of serum hsCRP</measure>
    <time_frame>2 years after cardiac surgery</time_frame>
    <description>Levels of serum hsCRP of atrial fibrillation after the cardiac surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of serum cytokines(IL-1β，IL-2R，IL-6，IL-8，IL-10，TNF-α)</measure>
    <time_frame>2 years after cardiac surgery</time_frame>
    <description>Levels of serum cytokines(IL-1β，IL-2R，IL-6，IL-8，IL-10，TNF-α) of atrial fibrillation after the cardiac surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation burden after cardiac surgery</measure>
    <time_frame>lidan2014@tjh.tjmu.edu.cn</time_frame>
    <description>Time and length of atrial fibrillation after cardiac surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Thromboembolic stroke</measure>
    <time_frame>2 years after cardiac surgery</time_frame>
    <description>Thromboembolic stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>Serious bleeding events</measure>
    <time_frame>2 years after cardiac surgery</time_frame>
    <description>Serious bleeding events</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>2 years after cardiac surgery</time_frame>
    <description>Cardiovascular, noncardiovascular or undetermined cause of death</description>
  </other_outcome>
  <other_outcome>
    <measure>Recurrence atrial fibrillaiton and readmission</measure>
    <time_frame>2 years after cardiac surgery</time_frame>
    <description>Recurrence atrial fibrillaiton and readmission</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Calcitonin Secretion Disorder</condition>
  <condition>Post-operative Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>POAF group</arm_group_label>
    <description>the patients will have atrial fibrillation following the cardiac surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-POAF group</arm_group_label>
    <description>the patients will have no atrial fibrillation following the cardiac surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Caridac surgery</intervention_name>
    <description>Cardiac surgery</description>
    <arm_group_label>POAF group</arm_group_label>
    <arm_group_label>non-POAF group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        It is expected that 200 patients who received the first non-emergency cardiopulmonary&#xD;
        bypass cardiac surgery in our hospital will be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Clinical diagnosis of no history of atrial fibrillation/flutter;&#xD;
&#xD;
          -  2. Heart rate ≥50 beats/min;&#xD;
&#xD;
          -  3. EF &gt; 40%;&#xD;
&#xD;
          -  4. No history of emergency cardiac surgery in our hospital;&#xD;
&#xD;
          -  5. Participate voluntarily and sign the informed consent, and can accept the follow-up&#xD;
             of more than 2 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Atrial fibrillation/flutter;&#xD;
&#xD;
          -  2. Left atrial diameter &gt;5.5cm;&#xD;
&#xD;
          -  3. Previous cardiac surgery or emergency surgery (&lt;12h);&#xD;
&#xD;
          -  4. Sick sinus node syndrome;&#xD;
&#xD;
          -  5. Ventricular preexcitation or preexcitation syndrome;&#xD;
&#xD;
          -  6. Second degree or above atrioventricular block;&#xD;
&#xD;
          -  7.Myocardial infarction occurred within 7 days;&#xD;
&#xD;
          -  8. Infection, sepsis, rheumatic or inflammatory diseases;&#xD;
&#xD;
          -  9. Abnormal liver and kidney function (three times higher than the upper limit of&#xD;
             normal);&#xD;
&#xD;
          -  10. Uncontrolled hyperthyroidism, severe obstructive sleep apnea, and acute&#xD;
             alcoholism;&#xD;
&#xD;
          -  11. Any ischemic events (stroke or TIA) that occurred 180 days before the participant&#xD;
             signed the informed consent, or any known unresolved complications from previous&#xD;
             stroke/TIA;Thrombosis;&#xD;
&#xD;
          -  12. Patients with other diseases requiring radiotherapy, chemotherapy and long-term&#xD;
             hormone therapy;&#xD;
&#xD;
          -  13. Patients' life expectancy makes it unlikely that follow-up will be completed;&#xD;
&#xD;
          -  14. Participate in, or are expected to participate in, other clinical trials of any&#xD;
             drugs, devices or biologics during the study period;&#xD;
&#xD;
          -  15. Patients with contraindications to dynamic electrocardiogram;&#xD;
&#xD;
          -  16. Patients who are unwilling or unable to fully comply with study procedures and&#xD;
             follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Ni, PHD</last_name>
      <phone>+862783662479</phone>
      <email>nili@tjh.tjmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 14, 2021</last_update_submitted>
  <last_update_submitted_qc>August 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Li Ni</investigator_full_name>
    <investigator_title>Division of Cardiology, Department of Internal Medicne</investigator_title>
  </responsible_party>
  <keyword>Post-operative atrial fibrillation</keyword>
  <keyword>Calcitonin</keyword>
  <keyword>Cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

